305 related articles for article (PubMed ID: 31900917)
1. Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance.
Yeh Y; Guo Q; Connelly Z; Cheng S; Yang S; Prieto-Dominguez N; Yu X
Adv Exp Med Biol; 2019; 1210():351-378. PubMed ID: 31900917
[TBL] [Abstract][Full Text] [Related]
2. Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
Khurana N; Sikka SC
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027362
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation.
Kim WK; Buckley AJ; Lee DH; Hiroto A; Nenninger CH; Olson AW; Wang J; Li Z; Vikram R; Adzavon YM; Yau TY; Bao Y; Kahn M; Geradts J; Xiao GQ; Sun Z
Nat Commun; 2024 Feb; 15(1):1231. PubMed ID: 38336745
[TBL] [Abstract][Full Text] [Related]
5. Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis.
Lee SH; Luong R; Johnson DT; Cunha GR; Rivina L; Gonzalgo ML; Sun Z
Oncogene; 2016 Feb; 35(6):702-14. PubMed ID: 25893287
[TBL] [Abstract][Full Text] [Related]
6. Activated Wnt/β-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer.
Bian P; Dou Z; Jia Z; Li W; Pan D
Life Sci; 2020 Aug; 254():116816. PubMed ID: 31472148
[TBL] [Abstract][Full Text] [Related]
7. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.
Terry S; Yang X; Chen MW; Vacherot F; Buttyan R
J Cell Biochem; 2006 Oct; 99(2):402-10. PubMed ID: 16741972
[TBL] [Abstract][Full Text] [Related]
8. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer.
Verras M; Sun Z
Cancer Lett; 2006 Jun; 237(1):22-32. PubMed ID: 16023783
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer.
Wang G; Wang J; Sadar MD
Cancer Res; 2008 Dec; 68(23):9918-27. PubMed ID: 19047173
[TBL] [Abstract][Full Text] [Related]
10. Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation.
Flores ML; Castilla C; Gasca J; Medina R; Pérez-Valderrama B; Romero F; Japón MA; Sáez C
Mol Cancer Ther; 2016 Jul; 15(7):1713-25. PubMed ID: 27196755
[TBL] [Abstract][Full Text] [Related]
11. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
Begemann D; Anastos H; Kyprianou N
Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
[TBL] [Abstract][Full Text] [Related]
12. A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.
Pakula H; Xiang D; Li Z
Cancers (Basel); 2017 Jan; 9(2):. PubMed ID: 28134791
[TBL] [Abstract][Full Text] [Related]
13. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
14. PHF21B overexpression promotes cancer stem cell-like traits in prostate cancer cells by activating the Wnt/β-catenin signaling pathway.
Li Q; Ye L; Guo W; Wang M; Huang S; Peng X
J Exp Clin Cancer Res; 2017 Jun; 36(1):85. PubMed ID: 28645312
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway.
Hsieh IS; Chang KC; Tsai YT; Ke JY; Lu PJ; Lee KH; Yeh SD; Hong TM; Chen YL
Carcinogenesis; 2013 Mar; 34(3):530-8. PubMed ID: 23188675
[TBL] [Abstract][Full Text] [Related]
16. MiR-182 promotes prostate cancer progression through activating Wnt/β-catenin signal pathway.
Wang D; Lu G; Shao Y; Xu D
Biomed Pharmacother; 2018 Mar; 99():334-339. PubMed ID: 29353209
[TBL] [Abstract][Full Text] [Related]
17. Wnt/β-catenin activation promotes prostate tumor progression in a mouse model.
Yu X; Wang Y; DeGraff DJ; Wills ML; Matusik RJ
Oncogene; 2011 Apr; 30(16):1868-79. PubMed ID: 21151173
[TBL] [Abstract][Full Text] [Related]
18. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells.
Liu XH; Kirschenbaum A; Yao S; Liu G; Aaronson SA; Levine AC
Cancer Res; 2007 Jun; 67(12):5747-53. PubMed ID: 17575141
[TBL] [Abstract][Full Text] [Related]
19. Aberrant androgen action in prostatic progenitor cells induces oncogenesis and tumor development through IGF1 and Wnt axes.
Kim WK; Olson AW; Mi J; Wang J; Lee DH; Le V; Hiroto A; Aldahl J; Nenninger CH; Buckley AJ; Cardiff R; You S; Sun Z
Nat Commun; 2022 Jul; 13(1):4364. PubMed ID: 35902588
[TBL] [Abstract][Full Text] [Related]
20. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
